Literature DB >> 11801540

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Fulvio Lonardo1, Konstantin H Dragnev, Sarah J Freemantle, Yan Ma, Natalie Memoli, David Sekula, Elisabeth A Knauth, Jean S Beebe, Ethan Dmitrovsky.   

Abstract

PURPOSE: There is a need to identify lung cancer prevention mechanisms. All-trans-retinoic acid (RA) was reported previously to inhibit N-nitrosamine-4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK) carcinogenic transformation of BEAS-2B human bronchial epithelial cells (J. Langenfeld et al., Oncogene, 13: 1983-1990, 1996). This study was undertaken to identify pathways targeted during this chemoprevention. EXPERIMENTAL
DESIGN: Because epidermal growth factor receptor (EGFR) overexpression is frequent in non-small cell lung cancers (NSCLC) and bronchial preneoplasia, BEAS-2B cells, carcinogen-transformed BEAS-2B(NNK) cells, and retinoid chemoprevented BEAS-2B(NNK RA) cells were each examined for EGFR expression. Whether RA treatment regulated directly EGFR expression or reporter plasmid activity was studied. RA effects on epidermal growth factor (EGF) induction of EGFR-phosphotyrosine levels, cyclin D1 expression and mitogenesis were examined in BEAS-2B cells.
RESULTS: Findings reveal that NNK-mediated transformation of BEAS-2B cells increased EGFR expression. RA treatment repressed EGFR expression and reporter plasmid activity in these cells. This treatment reduced EGF-dependent mitogenesis as well as EGFR-associated phosphotyrosine levels and cyclin D1 expression. These findings extend prior work by highlighting EGFR as a chemoprevention target in the lung. Notably, RA treatment prevented transformation as well as outgrowth of EGFR overexpressing bronchial epithelial cells, despite NNK exposure. After acute NNK exposure, p53-induced species that appear after DNA damage or oxidative stress were evident before an observed increase in EGFR expression.
CONCLUSIONS: These findings indicate how effective chemoprevention prevents carcinogenic transformation of bronchial epithelial cells when repair of genomic damage does not select against EGFR overexpressing cells. This implicates EGFR as a chemoprevention target in the carcinogen-exposed bronchial epithelium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801540

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

2.  Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Authors:  Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

Review 3.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Authors:  Fulvio Lonardo; Xiaohua Li; Alexander Kaplun; Ayman Soubani; Seema Sethi; Shirish Gadgeel; Shijie Sheng
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

4.  The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.

Authors:  Regan M Memmott; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

5.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Authors:  Collin M Blakely; Evangelos Pazarentzos; Victor Olivas; Saurabh Asthana; Jenny Jiacheng Yan; Irena Tan; Gorjan Hrustanovic; Elton Chan; Luping Lin; Dana S Neel; William Newton; Kathryn L Bobb; Timothy R Fouts; Jeffrey Meshulam; Matthew A Gubens; David M Jablons; Jeffrey R Johnson; Sourav Bandyopadhyay; Nevan J Krogan; Trever G Bivona
Journal:  Cell Rep       Date:  2015-04-02       Impact factor: 9.423

6.  EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.

Authors:  Vítor Sousa; Joana Espírito Santo; Maria Silva; Teresa Cabral; Ana Maria Alarcão; Ana Gomes; Patrícia Couceiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2011-03-22       Impact factor: 4.064

7.  UBE1L causes lung cancer growth suppression by targeting cyclin D1.

Authors:  Qing Feng; David Sekula; Yongli Guo; Xi Liu; Candice C Black; Fabrizio Galimberti; Sumit J Shah; Lorenzo F Sempere; Vincent Memoli; Jesper B Andersen; Bret A Hassel; Konstantin Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 8.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

9.  Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.

Authors:  I Abdel Salam; H E Gaballa; N Abdel Wahab
Journal:  Med Oncol       Date:  2008-12-18       Impact factor: 3.064

10.  Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Authors:  Chaolun An; Jiajun Zhang; Hongjun Chu; Chunyan Gu; Feng Xiao; Fengwei Zhu; Rujian Lu; Hai Shi; Hongfei Zhang; Xin Yi
Journal:  Pathol Oncol Res       Date:  2016-04-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.